Already have an account? Sign In
Maverick Therapeutics, founded in 2016 and headquartered in Brisbane, California, is a private biotechnology company specializing in innovative T-cell engagement therapies. The company's unique approach aims to address toxicity challenges associated with T-cell redirection therapy by developing therapeutic antibodies that remain inactive upon administration but become fully active in the tumor microenvironment.
Since its inception, Maverick Therapeutics has made significant strides in the biotechnology sector, raising a total of $56 million in funding. This financial backing demonstrates investor confidence in the company's potential and its novel therapeutic approach. However, it's important to note that on March 9th, 2021, Maverick Therapeutics was acquired by Takeda, a major pharmaceutical company.
Given the acquisition by Takeda, the prospects of a Maverick Therapeutics IPO are currently uncertain. As a subsidiary of a larger pharmaceutical company, the likelihood of an independent public offering has significantly decreased. Investors interested in gaining exposure to Maverick Therapeutics' technology and potential may need to consider Takeda's stock instead.
It's crucial to remember that the biotechnology industry is highly dynamic, and company situations can evolve rapidly. While we don't have specific information about Maverick Therapeutics' IPO prospects at this time, interested investors should continue to monitor official announcements from Takeda or Maverick Therapeutics for any updates regarding their future plans or potential spin-offs.
Already have an account? Sign In
While Maverick Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative biotech space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotechnology sector, including companies like Maverick Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and breakthroughs in cancer therapeutics before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.